The Correlation Between Genetic Polymorphism, Platelet Activity, Clopidogrel Responsiveness, and Serum Adipokine Concentration in Asian Acute Coronary Syndrome Patients
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by China Medical University Hospital.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
China Medical University Hospital
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01255267
First received: December 6, 2010
Last updated: NA
Last verified: December 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In this study, we evaluate the acute coronary syndrome patients to see if there is correlation between platelet activity, genetic polymorphism (CYP2C19 and ABCB1), serum adipokines level, and Clopidogrel responsiveness.
| Condition |
|---|
|
Acute Coronary Syndrome Chronic Coronary Artery Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Correlation Between Genetic Polymorphism, Platelet Activity, , Clopidogrel Responsiveness, and Serum Adipokine Concentration in Asian Acute Coronary Syndrome Patients |
Resource links provided by NLM:
MedlinePlus related topics:
Coronary Artery Disease
Drug Information available for:
Clopidogrel bisulfate
U.S. FDA Resources
Further study details as provided by China Medical University Hospital:
| Groups/Cohorts |
|---|
| Acute coronary syndrome patients |
| Chronic coronary artery disease patients |
| Healthy control |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Acute coronary syndrome and chronic coronary artery diseae patients
Criteria
Inclusion Criteria:
- Age > 18 y/o
- Acute coronary syndrome patients
- Chronic coronary artery disease patients
- Healthy volunteers
Exclusion Criteria:
- Patient refusal
- Allergy to Clopidogrel
- Receive Gp IIb/IIIa inhibitor simultaneously
- Cancer history
- Severe renal and liver function impairment
- Coagulopathy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01255267
Contacts
| Contact: Yu-Chen Wang, MD | 886-4-22052121 ext 2371 | richard9250@yahoo.com.tw |
Locations
| Taiwan | |
| China Medical University Hospital | Recruiting |
| Taichung, Taiwan | |
| Contact: Yu-Chen Wang, MD 886-4-22052121 ext 2371 richard9250@yahoo.com.tw | |
Sponsors and Collaborators
China Medical University Hospital
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT01255267 History of Changes |
| Other Study ID Numbers: | DMR99-IRB-041 |
| Study First Received: | December 6, 2010 |
| Last Updated: | December 6, 2010 |
| Health Authority: | Taiwan: Department of Health |
Keywords provided by China Medical University Hospital:
|
Acute coronary syndrome and chronic coronary artery disease patients |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Acute Coronary Syndrome Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Angina Pectoris Chest Pain Pain Signs and Symptoms |
Clopidogrel Platelet Aggregation Inhibitors Hematologic Agents Therapeutic Uses Pharmacologic Actions Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 19, 2013